Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 9864047, 8 pages
http://dx.doi.org/10.1155/2016/9864047
Review Article

New Progress of Epigenetic Biomarkers in Urological Cancer

Peng Wu,1,2,3,4 Ziyi Cao,1,2,4,5 and Song Wu1,2,4,6

1Department of Urological Surgery, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China
2Shenzhen Following Precision Medical Institute, Shenzhen Luohu Hospital Group, Shenzhen 518000, China
3First Clinical Medical College, Anhui Medical University, Hefei 230032, China
4Shenzhen Second People’s Hospital, 1st Affiliated Hospital of Shenzhen University, Shenzhen 518037, China
5Medical College, Shenzhen University, Shenzhen 518060, China
6Shenzhen Gene Detection Public Service Platform of Clinical Application, Shenzhen Luohu Hospital Group, Shenzhen 518000, China

Received 19 May 2016; Accepted 30 June 2016

Academic Editor: Maria L. Poeta

Copyright © 2016 Peng Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Catalona, P. C. Southwick, K. M. Slawin et al., “Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging,” Urology, vol. 56, no. 2, pp. 255–260, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Sharma, T. K. Kelly, and P. A. Jones, “Epigenetics in cancer,” Carcinogenesis, vol. 31, no. 1, pp. 27–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Vaissière, C. Sawan, and Z. Herceg, “Epigenetic interplay between histone modifications and DNA methylation in gene silencing,” Mutation Research/Reviews in Mutation Research, vol. 659, no. 1-2, pp. 40–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Lopez-Serra and M. Esteller, “Proteins that bind methylated DNA and human cancer: reading the wrong words,” British Journal of Cancer, vol. 98, no. 12, pp. 1881–1885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Perry, R. Foley, K. Woodson, and M. Lawler, “The emerging roles of DNA methylation in the clinical management of prostate cancer,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 357–377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. H. Waddington, “The epigenotype 1942,” International Journal of Epidemiology, vol. 41, no. 1, pp. 10–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. B. Y. Tsui, E. K. O. Ng, and Y. M. D. Lo, “Stability of endogenous and added RNA in blood specimens, serum, and plasma,” Clinical Chemistry, vol. 48, no. 10, pp. 1647–1653, 2002. View at Google Scholar · View at Scopus
  8. H. Easwaran, H.-C. Tsai, and S. B. Baylin, “Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance,” Molecular Cell, vol. 54, no. 5, pp. 716–727, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Sawan, T. Vaissière, R. Murr, and Z. Herceg, “Epigenetic drivers and genetic passengers on the road to cancer,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 642, no. 1-2, pp. 1–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. Weisenberger, “Characterizing DNA methylation alterations from the cancer genome atlas,” Journal of Clinical Investigation, vol. 124, no. 1, pp. 17–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Dudziec, S. Miah, H. M. Z. Choudhry et al., “Hypermethylation of CpG islands and shores around specific MicroRNAs and mirtrons is associated with the phenotype and presence of bladder cancer,” Clinical Cancer Research, vol. 17, no. 6, pp. 1287–1296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. Z.-G. Luo, Z.-G. Li, S.-L. Gui, B.-J. Chi, and J.-G. Ma, “Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer,” Journal of International Medical Research, vol. 42, no. 1, pp. 35–41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Lennartsson and K. Ekwall, “Histone modification patterns and epigenetic codes,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1790, no. 9, pp. 863–868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. A. Farazi, J. I. Hoell, P. Morozov, and T. Tuschl, “MicroRNAs in human cancer,” Advances in Experimental Medicine and Biology, vol. 774, pp. 1–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. C. B. Yoo and P. A. Jones, “Epigenetic therapy of cancer: past, present and future,” Nature Reviews Drug Discovery, vol. 5, no. 1, pp. 37–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Matzke and J. A. Birchler, “RNAi-mediated pathways in the nucleus,” Nature Reviews Genetics, vol. 6, no. 1, pp. 24–35, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Sato, S. Tsuchiya, S. J. Meltzer, and K. Shimizu, “MicroRNAs and epigenetics,” The FEBS Journal, vol. 278, no. 10, pp. 1598–1609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Weber, C. Stresemann, B. Brueckner, and F. Lyko, “Methylation of human microRNA genes in normal and neoplastic cells,” Cell Cycle, vol. 6, no. 9, pp. 1001–1005, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Lujambio and M. Esteller, “How epigenetics can explain human metastasis: a new role for microRNAs,” Cell Cycle, vol. 8, no. 3, pp. 377–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. E.-J. Kim, Y.-J. Kim, P. Jeong, Y.-S. Ha, S.-C. Bae, and W.-J. Kim, “Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor,” Journal of Urology, vol. 180, no. 3, pp. 1141–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-Y. Yoon, Y.-J. Kim, J. S. Kim et al., “RSPH9 methylation pattern as a prognostic indicator in patients with non-muscle invasive bladder cancer,” Oncology Reports, vol. 35, no. 2, pp. 1195–1203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Guil and M. Esteller, “DNA methylomes, histone codes and miRNAs: tying it all together,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 1, pp. 87–95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. L. Lin, Z. G. Li, Z. K. He, T. Y. Guan, and J. Q. Ma, “Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer,” Journal of International Medical Research, vol. 40, no. 6, pp. 2117–2123, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Wang, Y. Yu, R. Ye et al., “An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese,” Oncotarget, vol. 7, no. 3, pp. 2754–2764, 2016. View at Publisher · View at Google Scholar
  26. I. Renard, S. Joniau, B. van Cleynenbreugel et al., “Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples,” European Urology, vol. 58, no. 1, pp. 96–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Yates, I. Rehman, M. F. Abbod et al., “Promoter hypermethylation identifies progression risk in bladder cancer,” Clinical Cancer Research, vol. 13, no. 7, pp. 2046–2053, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A.-C. Schneider, L. C. Heukamp, S. Rogenhofer et al., “Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer,” BJU International, vol. 108, no. 8 B, pp. E290–E296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. An, H. Li, K. J. Wang et al., “Meta-analysis of the relationship between slow acetylation of N-acetyl transferase 2 and the risk of bladder cancer,” Genetics and Molecular Research, vol. 14, no. 4, pp. 16896–16904, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. Z.-M. Jia, X. Ai, J.-F. Teng, Y.-P. Wang, B.-J. Wang, and X. Zhang, “p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation,” Tumor Biology, vol. 37, no. 6, pp. 8293–8304, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Wang, R. Albadine, A. Magheli et al., “Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder,” Urologic Oncology: Seminars and Original Investigations, vol. 30, no. 4, pp. 428–433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Fabbri and G. A. Calin, “Epigenetics and miRNAs in human cancer,” Advances in Genetics, vol. 70, pp. 87–99, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Jiang, L. Du, W. Duan et al., “Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer,” Oncotarget, vol. 7, no. 24, pp. 36733–36742, 2016. View at Publisher · View at Google Scholar
  34. H. Sasaki, M. Yoshiike, S. Nozawa et al., “Expression level of urinary MicroRNA-146a-5p is increased in patients with bladder cancer and decreased in those after transurethral resection,” Clinical Genitourinary Cancer, 2016. View at Publisher · View at Google Scholar
  35. R. Matsushita, H. Yoshino, H. Enokida et al., “Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness,” Oncotarget, vol. 7, no. 19, 2016. View at Publisher · View at Google Scholar
  36. S. Hauser, T. Zahalka, G. Fechner, S. C. Müller, and J. Ellinger, “Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study,” Anticancer Research, vol. 33, no. 10, pp. 4651–4656, 2013. View at Google Scholar · View at Scopus
  37. M. de Martino, T. Klatte, A. Haitel, and M. Marberger, “Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker,” Cancer, vol. 118, no. 1, pp. 82–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Wang, J. Li, J. Gu et al., “Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma,” Oncology Letters, vol. 10, no. 5, pp. 3073–3080, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. Z. R. Wang, J. H. Wei, J. C. Zhou et al., “Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma,” Oncotarget, vol. 7, no. 21, 2016. View at Publisher · View at Google Scholar
  40. A. D. Goldberg, C. D. Allis, and E. Bernstein, “Epigenetics: a landscape takes shape,” Cell, vol. 128, no. 4, pp. 635–638, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. D. B. Seligson, S. Horvath, M. A. McBrian et al., “Global levels of histone modifications predict prognosis in different cancers,” The American Journal of Pathology, vol. 174, no. 5, pp. 1619–1628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Wang, R. Zhang, D. Wu et al., “Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma,” Journal of Experimental & Clinical Cancer Research, vol. 32, no. 1, article 8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. G. M. Zhang, L. Luo, X. M. Ding et al., “MicroRNA-126 inhibits tumor cell invasion and metastasis by downregulating ROCK1 in renal cell carcinoma,” Molecular Medicine Reports, vol. 13, pp. 5029–2036, 2016. View at Publisher · View at Google Scholar
  44. Z. Wotschofsky, L. Gummlich, J. Liep et al., “Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p,” PLOS ONE, vol. 11, no. 2, article e0148746, 2016. View at Publisher · View at Google Scholar
  45. A. Bettin, I. Reyes, and N. Reyes, “Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer,” The International Journal of Biological Markers, vol. 31, no. 2, pp. e153–e162, 2016. View at Publisher · View at Google Scholar
  46. C. Jerónimo and R. Henrique, “Epigenetic biomarkers in urological tumors: a systematic review,” Cancer Letters, vol. 342, no. 2, pp. 264–274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Dijkstra, I. L. Birker, F. P. Smit et al., “Prostate cancer biomarker profiles in urinary sediments and exosomes,” The Journal of Urology, vol. 191, no. 4, pp. 1132–1138, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Urquidi, C. J. Rosser, and S. Goodison, “Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis,” Current Medicinal Chemistry, vol. 19, no. 22, pp. 3653–3663, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. V. L. Costa, R. Henrique, S. A. Danielsen et al., “TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers,” Epigenetics, vol. 6, no. 9, pp. 1120–1130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Van Neste, R. J. Hendriks, S. Dijkstra et al., “Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score,” European Urology, 2016. View at Publisher · View at Google Scholar
  51. A. Ouhtit, M. N. Al-Kindi, P. R. Kumar, I. Gupta, S. Shanmuganathan, and Y. Tamimi, “Hoxb13, a potential prognostic biomarker for prostate cancer,” Frontiers in Bioscience, vol. 8, no. 1, pp. 40–45, 2016. View at Publisher · View at Google Scholar
  52. G. Hoyne, C. Rudnicka, Q.-X. Sang et al., “Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer,” BMC Cancer, vol. 16, no. 1, article 151, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Zheng, D. Sun, W. Fan, Z. Zhang, Q. Li, and T. Jiang, “Diagnostic value of SFRP1 as a favorable predictive and prognostic biomarker in patients with prostate cancer,” PLoS ONE, vol. 10, no. 2, article e0118276, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Tahara, H. Naito, K. Kise et al., “Evaluation of PSF1 as a prognostic biomarker for prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 18, no. 1, pp. 56–62, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Morgan, A. Boxall, A. Bhatt et al., “Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer,” Clinical Cancer Research, vol. 17, no. 5, pp. 1090–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Haldrup, A.-S. Lynnerup, T. M. Storebjerg et al., “Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels,” Molecular Oncology, vol. 10, no. 6, pp. 825–837, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. K. D. Berg, D. Soldini, M. Jung et al., “TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy,” Virchows Archiv, vol. 468, pp. 345–355, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. M. V. Russo, S. Esposito, M. G. Tupone et al., “SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis,” Oncotarget, vol. 7, no. 11, pp. 12372–12385, 2016. View at Publisher · View at Google Scholar
  59. J. Hao, Y. T. Chiang, P. W. Gout, and Y. Wang, “Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence,” Frontiers in Bioscience, vol. 8, no. 1, pp. 44–55, 2016. View at Publisher · View at Google Scholar
  60. F. Sanguedolce, A. Cormio, M. Brunelli et al., “Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review,” Clinical Genitourinary Cancer, vol. 14, no. 2, pp. 117–121, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Wang, H. Ye, D. Zhang et al., “MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer,” Cancer Cell International, vol. 16, no. 1, article 12, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Al-Kafaji, Z. T. Al-Naieb, and M. Bakhiet, “Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: a potential novel non-invasive biomarker,” Oncology Letters, vol. 11, no. 2, pp. 1201–1206, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Xu, X. M. Yi, W. Q. Zhou et al., “Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 11, pp. 14335–14344, 2015. View at Google Scholar
  64. A. E. Dago, A. Stepansky, A. Carlsson et al., “Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells,” PLoS ONE, vol. 9, no. 8, article e101777, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. J. G. Lohr, V. A. Adalsteinsson, K. Cibulskis et al., “Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer,” Nature Biotechnology, vol. 32, no. 5, pp. 479–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. M. J. M. Magbanua, E. V. Sosa, J. H. Scott et al., “Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer,” BMC Cancer, vol. 12, article 78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. W. Onstenk, W. de Klaver, R. de Wit, M. Lolkema, J. Foekens, and S. Sleijfer, “The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer,” Cancer Treatment Reviews, vol. 46, pp. 42–50, 2016. View at Publisher · View at Google Scholar
  68. O. Sartor and Y. Dong, “Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer,” Asian Journal of Andrology, vol. 17, no. 3, pp. 439–440, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Dellavedova, “Prostatic specific antigen. From its early days until becoming a prostate cancer biomarker,” Archivos Espanoles de Urologia, vol. 69, no. 1, pp. 19–23, 2016. View at Google Scholar · View at Scopus
  70. J. Ellinger, S. C. Müller, and D. Dietrich, “Epigenetic biomarkers in the blood of patients with urological malignancies,” Expert Review of Molecular Diagnostics, vol. 15, no. 4, pp. 505–516, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Li, R. W. Veltri, Z. Yuan, C. S. Christudass, and W. Mandecki, “Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer,” PLoS ONE, vol. 10, no. 4, Article ID e0122249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Mirabello, C. P. Kratz, S. A. Savage, and M. H. Greene, “Promoter methylation of candidate genes associated with familial testicular cancer,” International Journal of Molecular Epidemiology and Genetics, vol. 3, no. 3, pp. 213–227, 2012. View at Google Scholar · View at Scopus
  73. L. Mirabello, S. A. Savage, L. Korde, S. M. Gadalla, and M. H. Greene, “LINE-1 methylation is inherited in familial testicular cancer kindreds,” BMC Medical Genetics, vol. 11, article 77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. B.-F. Chen, S. Gu, Y.-K. Suen, L. Li, and W.-Y. Chan, “microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in testicular cancer,” Epigenetics, vol. 9, no. 1, pp. 119–128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Brait, L. Maldonado, S. Begum et al., “DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma,” British Journal of Cancer, vol. 106, no. 2, pp. 414–423, 2012. View at Publisher · View at Google Scholar · View at Scopus